GPX4 and non-small cell lung carcinoma: This inhibition promotes ferroptosis, which is mimicked by the GPX4 inhibitor RSL3, suggesting that targeting the miR-324-3p-GPX4 axis could effectively counteract cisplatin resistance in NSCLC (Deng et al., 2021).